Prognostic significance of CT-determined sarcopenia in patients with metastatic pulmonary adenocarcinoma

Authors

  • V. V. Kechedzhyiev Zaporizhzhia State Medical University, Ukraine, Ukraine
  • O. P. Kolesnik Zaporizhzhia State Medical University, Ukraine, Ukraine

DOI:

https://doi.org/10.14739/2310-1210.2021.2.228773

Keywords:

sarcopenia, lung adenocarcinoma, computed tomography, survival

Abstract

The aim. To determine the prognostic significance of computed tomography (CT)-determined sarcopenia in patients with metastatic pulmonary adenocarcinoma.

Materials and methods. Thirty patients with metastatic pulmonary adenocarcinoma who received polychemotherapy in the medical center “ONCOLIFE” from 2019 to 2020 were examined. The cross-sectional area was measured using archival CT images. The criteria of sarcopenia was skeletal muscle index at the level of the third lumbar vertebra <55 cm2/m2 for men and <39 cm2/m2 for women.

Results. Among 30 patients with stage IV non-squamous cell lung cancer, sarcopenia was present in 17 (56.6 %) cases. The median age at diagnosis was 62 years. Patients with sarcopenia had worse 1-year overall survival than those without sarcopenia (23.5 % vs. 65.9 %, respectively, P = 0.024 by the log-rank test). A statistically significant gender difference was not observed for survival.

Conclusions. CT-determined sarcopenia is an important prognostic marker in patients with metastatic pulmonary adenocarcinoma. Further study is needed to improve treatment outcomes of sarcopenia in patients with malignant neoplasms.

Author Biographies

V. V. Kechedzhyiev, Zaporizhzhia State Medical University, Ukraine

MD, PhD student of the Department of Oncology and Surgical Oncology

O. P. Kolesnik, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Oncology and Surgical Oncology

References

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424. https://doi.org/10.3322/caac.21492

Yang, M., Shen, Y., Tan, L., & Li, W. (2019). Prognostic Value of Sarcopenia in Lung Cancer: A Systematic Review and Meta-analysis. Chest, 156(1), 101-111. https://doi.org/10.1016/j.chest.2019.04.115

Shachar, S. S., Williams, G. R., Muss, H. B., & Nishijima, T. F. (2016). Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. European Journal of Cancer, 57, 58-67. https://doi.org/10.1016/j.ejca.2015.12.030

Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., Schneider, S. M., Sieber, C. C., Topinkova, E., Vandewoude, M., Visser, M., Zamboni, M., Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), & Extended Group for EWGSOP2. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age and ageing, 48(1), 16-31. https://doi.org/10.1093/ageing/afy169

Peng, P., Hyder, O., Firoozmand, A., Kneuertz, P., Schulick, R. D., Huang, D., Makary, M., Hirose, K., Edil, B., Choti, M. A., Herman, J., Cameron, J. L., Wolfgang, C. L., & Pawlik, T. M. (2012). Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma. Journal of Gastrointestinal Surgery, 16(8), 1478-1486. https://doi.org/10.1007/s11605-012-1923-5

Smith, A. B., Deal, A. M., Yu, H., Boyd, B., Matthews, J., Wallen, E. M., Pruthi, R. S., Woods, M. E., Muss, H., & Nielsen, M. E. (2014). Sarcopenia as a Predictor of Complications and Survival Following Radical Cystectomy. The Journal of Urology, 191(6), 1714-1720. https://doi.org/10.1016/j.juro.2013.12.047

Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., Murphy, R., Ghosh, S., Sawyer, M. B., & Baracos, V. E. (2013). Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index. Journal of Clinical Oncology, 31(12), 1539-1547. https://doi.org/10.1200/JCO.2012.45.2722

Rossi, F., Valdora, F., Bignotti, B., Torri, L., Succio, G., & Tagliafico, A. S. (2019). Evaluation of body Computed Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: A systematic review. Cancer Treatment and Research Communications, 21, Article 100154. https://doi.org/10.1016/j.ctarc.2019.100154

Rier, H. N., Jager, A., Sleijfer, S., Maier, A. B., & Levin, M. D. (2016). The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. The Oncologist, 21(11), 1396-1409. https://doi.org/10.1634/theoncologist.2016-0066

Kazemi-Bajestani, S. M., Mazurak, V. C., & Baracos, V. (2016). Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Seminars in Cell & Developmental Biology, 54, 2-10. https://doi.org/10.1016/j.semcdb.2015.09.001

Portal, D., Hofstetter, L., Eshed, I., Dan-Lantsman, C., Sella, T., Urban, D., Onn, A., Bar, J., & Segal, G. (2019). L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients. Cancer Management and Research, 11, 2579-2588. https://doi.org/10.2147/CMAR.S195869

Kimura, M., Naito, T., Kenmotsu, H., Taira, T., Wakuda, K., Oyakawa, T., Hisamatsu, Y., Tokito, T., Imai, H., Akamatsu, H., Ono, A., Kaira, K., Murakami, H., Endo, M., Mori, K., Takahashi, T., & Yamamoto, N. (2015). Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Supportive Care in Cancer, 23(6), 1699-1708. https://doi.org/10.1007/s00520-014-2534-3

Chambard, L., Girard, N., Ollier, E., Rousseau, J. C., Duboeuf, F., Carlier, M. C., Brevet, M., Szulc, P., Pialat, J. B., Wegrzyn, J., Clezardin, P., & Confavreux, C. B. (2018). Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. Bone, 108, 202-209. https://doi.org/10.1016/j.bone.2018.01.004

Gomez-Perez, S. L., Haus, J. M., Sheean, P., Patel, B., Mar, W., Chaudhry, V., McKeever, L., & Braunschweig, C. (2016). Measuring Abdominal Circumference and Skeletal Muscle From a Single Cross-Sectional Computed Tomography Image: A Step-by-Step Guide for Clinicians Using National Institutes of Health ImageJ. JPEN. Journal of Parenteral and Enteral Nutrition, 40(3), 308-318. https://doi.org/10.1177/0148607115604149

Gomez-Perez, S., McKeever, L., & Sheean, P. (2020). Tutorial: A Step-by-Step Guide (Version 2.0) for Measuring Abdominal Circumference and Skeletal Muscle From a Single Cross-Sectional Computed-Tomography Image Using the National Institutes of Health ImageJ. JPEN. Journal of Parenteral and Enteral Nutrition, 44(3), 419-424. https://doi.org/10.1002/jpen.1721

Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., Davis, M., Muscaritoli, M., Ottery, F., Radbruch, L., Ravasco, P., Walsh, D., Wilcock, A., Kaasa, S., & Baracos, V. E. (2011). Definition and classification of cancer cachexia: an international consensus. The Lancet. Oncology, 12(5), 489-495. https://doi.org/10.1016/S1470-2045(10)70218-7

Järvinen, T., Ilonen, I., Kauppi, J., Volmonen, K., Salo, J., & Räsänen, J. (2018). Low skeletal muscle mass in stented esophageal cancer predicts poor survival: A retrospective observational study. Thoracic Cancer, 9(11), 1429-1436. https://doi.org/10.1111/1759-7714.12855

Ubachs, J., Ziemons, J., Minis-Rutten, I., Kruitwagen, R., Kleijnen, J., Lambrechts, S., Olde Damink, S., Rensen, S. S., & Van Gorp, T. (2019). Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 10(6), 1165-1174. https://doi.org/10.1002/jcsm.12468

Caan, B. J., Cespedes Feliciano, E. M., Prado, C. M., Alexeeff, S., Kroenke, C. H., Bradshaw, P., Quesenberry, C. P., Weltzien, E. K., Castillo, A. L., Olobatuyi, T. A., & Chen, W. Y. (2018). Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncology, 4(6), 798-804. https://doi.org/10.1001/jamaoncol.2018.0137

Lee, J. S., Kim, Y. S., Kim, E. Y., & Jin, W. (2018). Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer. PLOS ONE, 13(8), Article e0202700. https://doi.org/10.1371/journal.pone.0202700

Nishioka, N., Uchino, J., Hirai, S., Katayama, Y., Yoshimura, A., Okura, N., Tanimura, K., Harita, S., Imabayashi, T., Chihara, Y., Tamiya, N., Kaneko, Y., Yamada, T., & Takayama, K. (2019). Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. Journal of Clinical Medicine, 8(4), Article 450. https://doi.org/10.3390/jcm8040450

Stene, G. B., Helbostad, J. L., Amundsen, T., Sørhaug, S., Hjelde, H., Kaasa, S., & Grønberg, B. H. (2015). Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncologica, 54(3), 340-348. https://doi.org/10.3109/0284186X.2014.953259

Dhillon, R. J., & Hasni, S. (2017). Pathogenesis and Management of Sarcopenia. Clinics in Geriatric Medicine, 33(1), 17-26. https://doi.org/10.1016/j.cger.2016.08.002

Published

2021-04-16

How to Cite

1.
Kechedzhyiev VV, Kolesnik OP. Prognostic significance of CT-determined sarcopenia in patients with metastatic pulmonary adenocarcinoma. Zaporozhye Medical Journal [Internet]. 2021Apr.16 [cited 2024Nov.24];23(2):231-5. Available from: http://zmj.zsmu.edu.ua/article/view/228773

Issue

Section

Original research